Open AccessFirst-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
Author(s) -
Ewoud-Jan van Hoogdalem,
Cacha Peeters-Scholte,
Paul W.T.J. Leufkens,
Jan Hartstra,
Jan Jaap van Lier,
L. G. J. de Leede
Publication year - 2020
Publication title -
current clinical pharmacology
Language(s) - English
Resource type - Journals
eISSN - 2212-3938
pISSN - 1574-8847
DOI - 10.2174/1574884714666191017111109
Subject(s) - tolerability , medicine , pharmacokinetics , placebo , dosing , volume of distribution , neuroprotection , ischemia , hypoxia (environmental) , anesthesia , pharmacology , adverse effect , chemistry , alternative medicine , organic chemistry , pathology , oxygen
2-iminobiotin (2-IB) is an investigational neuroprotective agent in development for the reduction of brain cell injury after cerebral hypoxia-ischemia.